The sequence of the Alzheimer amyloid peptide (beta-protein) is part of the sequence predicted from at least three distinct cDNA species which derive from the same gene by alternative splicing. Each of the two longer forms of the amyloid peptide precursors (APP) contains at least one additional sequence of 56 residues. The mechanism by which beta-protein derives from APPs is not known. However, evidence suggests that APP may be a cell surface and/or a secreted protein. We have hypothesized that amyloid peptide may derive as a result of abnormal post-translational processing of the APP including dysfunctional endocytosis, lysosomal degradation, recycling of cell-surface APP, or glycosylation. Recent work indicates that the three forms of APP may be differentially expressed both in different mammalian brains and within different regions of the human brain. Specifically, it seems that in both normal and AD brains the insert containing APPS are present only in the regions involved in plaque formation. We propose to use anti-APP antisera to (a) describe the topographical expression of the different APP forms in normal and AD brains, (b) since the insert containing APP seems to be absent from the rodent brain, we would like to study the expression of the APP 751 in transgenic mice and (c) determine the proteolytic modifications, phosphorylation, membrane interactions, endocytosis and lysosomal degradation of the APP. Production of beta-protein could be due to abnormalities involving any one of these pathways.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-07
Application #
3809198
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Warren, Noel A; Voloudakis, Georgios; Yoon, Yonejung et al. (2018) The product of the ?-secretase processing of ephrinB2 regulates VE-cadherin complexes and angiogenesis. Cell Mol Life Sci 75:2813-2826

Showing the most recent 10 out of 555 publications